Category: Amgen
-
Amgen must pay $20.2 million in damages over antibody patent infringement: District of Delaware jury
Following a trial in the United States District Court for the District of Delaware last week, a jury has found that Amgen’s subsidiary Teneobio has infringed one of competitor Harbour Antibodies’s antibody-related patents and owes over $20 million in damages.
-
UPC CoA reverses invalidation of Amgen patent, clarifies standards for added matter and sufficient disclosure; infringement action to resume
In a high-stakes life sciences case, the UPC’s CoA has provided its most far-reaching clarifications on (in)validity to date.